AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
AZ/Merck & Co reveal data supporting PARP drug in prostate cancerPARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest Share XAZ/Merck & Co reveal data supporting PARP drug in prostate cancerhttps://pharmaphorum.com/news/az-merck-co-reveal-data-supporting-parp-drug-in-prostate-cancer/
J&J unveils early-stage prostate cancer data from Erleada at ASCOJohnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients Share XJ&J unveils early-stage prostate cancer data from Erleada at ASCOhttps://pharmaphorum.com/news/jj-unveils-early-stage-prostate-cancer-data-from-erleada-at-asco/
Bayer files prostate cancer drug darolutamide with EU regulatorsAfter filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer Share XBayer files prostate cancer drug darolutamide with EU regulatorshttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-with-eu-regulators/
Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Bayer completes US filing for prostate cancer drug darolutamideBayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share XBayer completes US filing for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
